Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory Hodgkin and non-Hodgkin's lymphoma in Iran

Nahid, Hatam; Mehdi, Dehghani; Mostafa, Habibian; Abdosaleh, Jafari

Nahid, Hatam; Mehdi, Dehghani; Mostafa, Habibian; Abdosaleh, Jafari.

Iranian Journal of Cancer Prevention. 2015; 8 (5): 59-66

in English | IMEMR | ID: emr-175782

ABSTRACT

ABSTRACT

Background:

Chemotherapy for lymph nodes cancer is often composed of several drugs that are used in a treatment program

Subject(s)

Humans; Male; Female; Adult; Lymphoma, Non-Hodgkin/drug therapy; Hodgkin Disease/drug therapy; Ifosfamide; Epirubicin; Etoposide; Methylprednisolone; Cytarabine; Cisplatin; Cross-Sectional Studies

Search on Google

XML

Index: IMEMR (Eastern Mediterranean) Main subject: Lymphoma, Non-Hodgkin / Hodgkin Disease / Methylprednisolone / Epirubicin / Cross-Sectional Studies / Cisplatin / Cytarabine / Etoposide / Ifosfamide Type of study: Health economic evaluation / Prevalence study Limits: Adult / Female / Humans / Male Language: English Journal: Iran. J. Cancer Prevention Year: 2015

Similar

MEDLINE

LILACS

LIS

Search on Google

XML